RANTES production by T cells and CD8-mediated inhibition of human immunodeficiency virus gene expression before initiation of potent antiretroviral therapy predict sustained suppression of viral replication

Journal of Infectious Diseases

Volumn 181, Issue 2, 2000, Pages 505-512

  Fransen, Signe ^a   Copeland, Karen F T ^b   Smieja, Marek ^a   Smaill, Fiona ^a   Rosenthal, Kenneth L ^a  

^a MCMASTER UNIVERSITY MEDICAL CENTRE   (Canada)

^b OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CD8 ANTIGEN; LAMIVUDINE; RANTES; SAQUINAVIR; ZIDOVUDINE;

ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG FORMULATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; T LYMPHOCYTE; VIRUS INHIBITION; VIRUS LOAD;

ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; CD8-POSITIVE T-LYMPHOCYTES; GENE EXPRESSION; HIV INFECTIONS; HIV LONG TERMINAL REPEAT; HIV-1; HUMANS; LAMIVUDINE; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; RANTES; REVERSE TRANSCRIPTASE INHIBITORS; RNA, VIRAL; SAQUINAVIR; SINGLE-BLIND METHOD; T-LYMPHOCYTES; VIRAL LOAD; VIRUS REPLICATION; ZIDOVUDINE;

EID: 0034051756     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/315270     Document Type: Article

References (52)

1. Hogg RS, O'Shaughnessy MV, Gataric N, et al. Decline in deaths from AIDS due to new antiretrovirals [letter]. Lancet 1997; 349:1294.
2. Needham DM, Hogg RS, Yip B, O'Shaughnessy M, Schechter MT, Montaner JS. The impact of antiretroviral therapy on AIDS survival observed in a province-wide drug treatment programme [letter], Int JSTD AIDS 1998; 9:370-2.
3. Hammer SM. Advances in antiretroviral therapy and viral load monitoring. AIDS 1996; 10(Suppl 3):S1-11.
4. Hogg RS, Heath KV, Yip B, et al. Improved survival among HIV-infected individuals following initiation of antiretroviral therapy [see comments]. JAMA 1998; 279:450-4.
5. + cell suppressor factors and cytotoxic T lymphocytes during HIV infection. AIDS Res Hum Retroviruses 1998; 14(Suppl 2):S153-60.
6. + cell anti-HIV activity correlates with the clinical state of the infected individual. J Clin Invest 1991; 87:1462-6.
7. Carmichael A, Jin X, Sissons P, Borysiewicz L. Quantitative analysis of the human immunodeficiency virus type 1 (HIV-1)-specific cytotoxic T lymphocyte (CTL) response at different stages of HIV-1 infection: differential CTL responses to HIV-1 and Epstein-Barr virus in late disease. J Exp Med 1993; 177:249-56.
8. Walker BD, Plata F. Cytotoxic T lymphocytes against HIV. AIDS 1990; 4:177-84.
9. + T cells [see comments]. Science 1995; 270:1811-5.
10. + cells is mediated by the chemokine receptor CC-CKR-5 [see comments]. Nature 1996; 381:667-73.
11. Deng H, Liu R, Ellmeier W, et al. Identification of a major co-receptor for primary isolates of HIV-1 [see comments]. Nature 1996; 381:661-6.
12. Feng Y, Broder CC, Kennedy PE, Berger EA. HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor [see comments]. Science 1996; 272:872-7.
13. Connor RI, Sheridan KE, Ceradini D, Choe S, Landau NR. Change in coreceptor use correlates with disease progression in HIV-1-infected individuals. J Exp Med 1997; 185:621-8.
14. Scarlatti G, Tresoldi E, Bjorndal A, et al. In vivo evolution of HIV-1 co-receptor usage and sensitivity to chemokine-mediated suppression. Nat Med 1997; 3:1259-65.
15. Xiao L, Rudolph DL, Owen SM, Spira TJ, Lal RB. Adaptation to promiscuous usage of CC and CXC-chemokine coreceptors in vivo correlates with HIV-1 disease progression. AIDS 1998; 12:F137-43.
16. Alkhatib G, Combadiere C, Broder CC, et al. CC CKR5: a RANTES, MIP- lα, MIP-lβ receptor as a fusion cofactor for macrophagetropic HIV-1, Science 1996; 272:1955-8.
17. + T-cell mediated suppression of HIV-1 long terminal repeat-driven gene expression is not modulated by the CC chemokines RANTES, macrophage inflammatory protein (MIP) 1 alpha and MIP-1 beta. AIDS 1997; 11:575-80.
18. Mackewicz CE, Barker E, Levy JA. Role of beta-chemokines in suppressing HIV replication [letter; comment]. Science 1996; 274:1393-5.
19. + T-cell clones. AIDS 1996; 10:1317-21.
20. + lymphocytes as prognostic markers of HIV-1 infection [see comments]. Ann Intern Med 1997; 126:946-54.
21. Carpenter CC, Fischl MA, Hammer SM, et al. Antiretroviral therapy for HIV infection in 1998: updated recommendations of the International AIDS Society-USA Panel. JAMA 1998; 280:78-86.
22. Polo S, Veglia F, Malnati MS, et al. Longitudinal analysis of serum chemokine levels in the course of HIV-1 infection. AIDS 1999; 13:447-54.
23. Krowka JF, Gesner ML, Ascher MS, Sheppard HW. Lack of associations of chemotactic cytokines with viral burden, disease progression, or lymphocyte subsets in HIV-infected individuals. Clin Immunol Immunopathol 1997; 85:21-7.
24. Weiss L, Si-Mohamed A, Giral P, et al. Plasma levels of monocyte chemoattractant protein 1 but not those of macrophage inhibitory protein 1α and RANTES correlate with virus load in human immunodeficiency virus infection. J Infect Dis 1997; 176:1621-4.
25. McKenzie SW, Dallalio G, North M, Frame P, Means RT Jr. Serum chemokine levels in patients with non-progressing HIV infection. AIDS 1996; 10:F29-33.
26. Zanussi S, D'Andrea M, Simonelli C, Tirelli U, De Paoli P. Serum levels of RANTES and MIP-1 alpha in HIV-positive long-term survivors and progressor patients [letter], AIDS 1996; 10:1431-2.
27. Aukrust P, Muller F, Froland SS. Circulating levels of RANTES in human immunodeficiency virus type 1 infection: effect of potent antiretroviral therapy. J Infect Dis 1998; 177:1091-6.
28. +, T-cell clones correlates with the clinical state of human immunodeficiency virus type 1 (HIV-1) infected individuals and may be responsible for blocking infection with non-syncytium-inducing HIV-1 in vitro. J Virol 1998; 72:876-81.
29. Scala E, D'Offizi G, Rosso R, et al. C-C chemokines, IL.-16, and soluble antiviral factor activity are increased in cloned T cells from subjects with long-term nonprogressive HIV infection. J Immunol 1997; 158:4485- 92.
30. Bisset LR, Rothen M, Joller-Jemelka HI, Dubs RW, Grob PJ, Opravil M. Change in circulating levels of the chemokines macrophage inflammatory proteins 1 alpha and 11 beta, RANTES, monocyte chemotactic protein 1 and interleukin-16 following treatment of severely immunodeficient HIV- infected individuals with indinavir. AIDS 1997; 11:485-91.
31. Berkhout B, Silverman RH, Jeang KT. Tat trans-activates the human immunodeficiency virus through a nascent RNA target. Cell 1989; 59:273-82.
32. Peterlin BM, Luciw PA, Barr PJ, Walker MD. Elevated levels of mRNA can account for the trans-activation of human immunodeficiency virus. Proc Natl Acad Sci U S A 1986; 83:9734-8.
33. Queen C, Baltimore D. Immunoglobulin gene transcription is activated by downstream sequence elements. Cell 1983; 33:741-8.
34. Harada S, Koyanagi Y, Yamamoto N. Infection of human T-lymphotropic virus type-1 (HTLV-I) bearing MT-4 cells with HTLV-III (AIDS virus): chronological studies of early events. Virology 1985; 146:272-81.
35. Mitsuyasu RT, Skolnik PR, Cohen SR, et al. Activity of the soft gelatin formulation of saquinavir in combination therapy in antiretroviral-naive patients: NV15355 Study Team. AIDS 1998; 12:F103-9.
36. Ward SG, Bacon K, Westwick J. Chemokines and T lymphocytes: more than an attraction. Immunity 1998; 9:1-11.
37. Mosier DE, Picchio GR, Gulizia RJ, et al. Highly potent RANTES analogues either prevent CCR5-using human immunodeficiency virus type 1 infection in vivo or rapidly select for CXCR4-using variants. J Virol 1999; 73:3544-50.
38. Simmons G, Clapham PR, Picard L, et al. Potent inhibition of HIV-1 infectivity in macrophages and lymphocytes by a novel CCR5 antagonist. Science 1997; 276:276-9.
39. Klinger MH, Wilhelm D, Bubel S, Sticherling M, Schroder JM, Kuhnel W. Immunocytochemical localisation of the chemokines RANTES and MIP-1 alpha within human platelets and their release during storage. Int Arch Allergy Immunol 1995; 107:541-6.
40. Kameyoshi Y, Dorschner A, Mallet AI, Christophers E, Schroder JM. Cytokine RANTES released by thrombin-stimulated platelets is a potent attractant for human eosinophils. J Exp Med 1992; 176:587-92.
41. Hadida F, Vieillard V, Autran B, Clark-Lewis I, Baggiolini M, Debre P. HIV- specific T cell cytotoxicity mediated by RANTES via the chemokine receptor CCR3. J Exp Med 1998; 188:609-14.
42. Hadida F, Vieillard V, Mollet L, Clark-Lewis I, Baggiolini M, Debr P. Cutting edge: RANTES regulates fas ligand expression and killing by HIV-specific CD8 cytotoxic T cells. J Immunol 1999; 163:1105-9.
43. Clerici M, Shearer GM. A TH1→TH2 switch is a critical step in the etiology of HIV infection [see comments]. Immunol Today 1993; 14:107-11.
44. + T helper cell depletion occurs. J Clin Invest 1988; 82:1908-14.
45. + cell numbers and clinical staging. J Clin Invest 1989; 84:1892-9.
46. + lymphocytes can control HIV infection in vitro by suppressing virus replication. Science 1986; 234:1563-6.
47. + cells varies among infected individuals. Cell Immunol 1989; 119:470-5.
48. + T cell phenotype correlates with anti-HIV activity and asymptomatic clinical status. Clin Immunol Immunopathol 1993; 69:106-16.
49. + T cells correlates with CD4 counts and clinical stage of disease. Clin Exp Immunol 1994; 97:68-75.
50. +) cell noncytotoxic anti-HIV response. Proc Natl Acad Sci USA 1999; 96:1030-5.
51. + T cells is not lentivirus specific. AIDS Res Hum Retroviruses 1995; 11:1321-6.
52. + T cells is dependent on the NFAT-l element. AIDS Res Hum Retroviruses 1996; 12:143-8.